NCT02989402 - A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type. | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

December 31, 2018

Primary Completion Date

December 7, 2022

Study Completion Date

December 8, 2022

Conditions

Alzheimer's Disease

Interventions

DRUG

Rivastigmine

15 cm\^2 patch sizes loaded with 27 mg of rivastigmine - one patch per day

Trial Locations (9)

Novartis Investigative Site, Lucknow

Novartis Investigative Site, Hyderabad

Novartis Investigative Site, Bengaluru

Novartis Investigative Site, Bangalore

Novartis Investigative Site, Banglaore

Novartis Investigative Site, Kolkata

Novartis Investigative Site, Kolkata

Novartis Investigative Site, Bangalore

Novartis Investigative Site, Mumbai